Orvosi hetilap · 2010
[Management of Fabry disease].
Аннотация на английскомСтатьяКлинические рекомендацииОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Constantin Tamás, Székely Annamária, Ponyi Andrea, Gulácsy Vera, Ambrus Csaba, Kádár Krisztina, Vastagh Ildikó, Dajnoki Angéla, Tóth Beáta, Bokrétás Gergely, Müller Veronika, Katona Mária, Medvecz Márta, Fiedler Orsolya, Széchey Rita, Varga Edit, Rudas Gábor, Kertész Attila, Molnár Sándor, Kárpáti Sarolta, Nagy Viktor, Magyar Pál, Mahdi Mohamed, Rákóczi Eva, Németh Krisztina, Bereczki Dániel, Garami Miklós, Erdos Melinda, Maródi László, Fekete György
Аннотация
Fabry disease is a rare, X-linked lysosomal storage disorder that leads to accumulation of globotriaosylceramide in different tissues of the body. The disease is progressive and the first symptoms usually present in childhood. Consequences of the disease are disability and premature death. The disease in females could be as severe as in males although women may be asymptomatic. The possibility of enzyme replacement therapy has made it necessary to elaborate a comprehensive guideline for the diagnosis and treatment follow-up. The guideline has been summarized by a Hungarian multi-disciplinary working group consisting of physicians who are involved in diagnosis and care of Fabry patients. Previous clinical studies, published articles, and recently established international treatment guidelines were reviewed by the group.